Table 1.
Characteristics of studies included in the meta-analysis
| Surname | Year | Country | Ethnicity | Cancer type | Control source | Genotype method | NO. of cases | NO. of control | MAF | HWE | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||||
| All | AA | AG | GG | All | AA | AG | GG | |||||||||
| Berndt | 2007 | USA | European | Colorectal | PB | TaqMan | 229 | 101 | 101 | 27 | 2081 | 1063 | 851 | 167 | 0.28 | 0.855 |
| Conde | 2009 | Portugal | European | Breast | HB | TaqMan | 286 | 121 | 129 | 36 | 544 | 246 | 240 | 58 | 0.33 | 0.962 |
| Hirata | 2008 | Japan | Asian | Prostate | HB | SSCP/PCR-RFLP | 110 | 60 | 43 | 7 | 110 | 72 | 31 | 7 | 0.20 | 0.160 |
| Jafary | 2012 | Iran | Asian | Prostate | PB | SSCP | 18 | 12 | 5 | 1 | 60 | 34 | 18 | 8 | 0.28 | 0.043 |
| Kawakami | 2004 | Japan | Asian | Bladder | PB | SSCP | 99 | 53 | 38 | 8 | 101 | 66 | 28 | 7 | 0.21 | 0.112 |
| Orimo | 2000 | Japan | Asian | Colorectal | PB | SSCP | 19 | 10 | 8 | 1 | 89 | 55 | 28 | 6 | 0.22 | 0.360 |
| Shi | 2008 | China | Asian | Thyroid | HB | PCR-RFLP | 204 | 120 | 68 | 16 | 204 | 130 | 60 | 14 | 0.22 | 0.062 |
| Smith | 2008 | USA | European | Breast | HB | MassARRAY | 321 | 154 | 123 | 44 | 409 | 198 | 175 | 36 | 0.30 | 0.762 |
| African | Breast | HB | MassARRAY | 52 | 21 | 23 | 8 | 72 | 33 | 29 | 10 | 0.34 | 0.383 | |||
| Song | 2006 | UK | European | Ovarian | PB | TaqMan | 1310 | 663 | 525 | 122 | 2003 | 1064 | 771 | 168 | 0.28 | 0.093 |
| Terrazzino | 2012 | Italy | European | Breast | HB | TaqMan | 89 | 41 | 36 | 12 | 196 | 93 | 86 | 17 | 0.31 | 0.646 |
| Vogelsang | 2012 | South Africa | African | Oesophageal | HB | TaqMan | 545 | 204 | 256 | 85 | 607 | 230 | 295 | 82 | 0.38 | 0.410 |
SSCP, single-strand conformational polymorphism; PCR-RFLP, polymerase chain reaction restriction fragment length polymorphisms; HB, hospital based; PB, population based; MAF, Minor Allele Frequency; HWE: Hardy-Weinberg equilibrium.